TRT After 50: The Evidence
For decades, testosterone therapy in older men was approached with caution bordering on avoidance. Concerns about cardiovascular risk and prostate cancer dominated the conversation. The TRAVERSE trial, published with results from over 5,000 men with a mean age of 63, fundamentally changed this landscape. It demonstrated that TRT does not increase the risk of major adverse cardiovascular events and confirmed benefits across multiple domains relevant to aging men.
This does not mean TRT is appropriate for every man over 50. But it means the risk-benefit calculation has shifted dramatically in favor of treatment for men with confirmed deficiency and symptomatic burden.
Cardiovascular Safety
The TRAVERSE trial followed men at elevated cardiovascular risk for an average of 33 months. TRT did not increase the rate of major adverse cardiovascular events including heart attack, stroke, or cardiovascular death. In fact, observational data suggests that restoring testosterone to normal levels may be cardiovascular protective through improvements in insulin sensitivity, body composition, and lipid profiles.
Men on TRT should still monitor cardiovascular risk factors. Hematocrit can rise, increasing blood viscosity, which is manageable with dose adjustment or therapeutic phlebotomy. Blood pressure should be tracked. But the fear of TRT causing heart attacks has been definitively addressed.
Bone and Body Composition
After 50, bone density loss accelerates. Testosterone is directly anabolic to bone, stimulating osteoblast activity and reducing bone resorption. Studies show that TRT increases bone mineral density at the spine and hip in men with low testosterone, reducing fracture risk. Given that hip fractures in men over 65 carry a 30% one-year mortality rate, this benefit is not trivial.
Body composition improvements remain robust in older men on TRT. Fat mass decreases and lean mass increases, even without changes in exercise or diet. When combined with resistance training, the magnitude of these changes is greater.
Cognitive Benefits
Cognitive decline is a primary concern for men over 50. While TRT is not a treatment for dementia, research shows improvements in verbal memory, spatial reasoning, and processing speed in men with low testosterone who receive treatment. These cognitive benefits are most pronounced in men whose levels were in the clearly deficient range before treatment.
Prostate Considerations
The historical concern that testosterone causes or accelerates prostate cancer has been largely dispelled. The saturation model, supported by extensive research, demonstrates that prostate tissue is maximally stimulated at relatively low testosterone levels. Raising testosterone from low to normal does not increase prostate stimulation. Current evidence shows no increased risk of prostate cancer diagnosis in men on TRT.
That said, PSA should be monitored at baseline and every six months during the first year of treatment. Any significant rise warrants evaluation. Men with active prostate cancer should not receive TRT, though men with successfully treated prostate cancer may be candidates after appropriate surveillance.
Starting Safely
Starting TRT after 50 requires more thorough baseline evaluation than in younger men. In addition to standard hormone panels, testing should include PSA, digital rectal exam, DEXA scan for bone density baseline, cardiac risk assessment, and sleep study if sleep apnea is suspected. Starting doses may be lower, typically 80-100 mg per week of testosterone cypionate, with gradual titration based on response. The goal is symptom improvement with testosterone levels in the mid-normal range, not the upper limit.